Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
TegMine bags tech from OBI to help fuel ADC ambitions
TegMine has landed certain rights to OBI's ADC tech, advancing the efforts of former Stemcentrx scientists to treat cancer by targeting carbohydrates.
Nick Paul Taylor
Jun 6, 2025 10:00am
Merck takes middle dose of ROR ADC forward into phase 3
May 30, 2025 9:51am
Endometrial cancer data on Genmab's Elahere rival beat forecast
May 23, 2025 9:22am
ADC Therapeutics calls time on sole clinical-stage candidate
May 14, 2025 9:55am
Mersana lays off 55% of staff, narrows focus to B7-H4 ADC
May 6, 2025 9:40am
Elevation faces activist investor demands to wind down
Apr 17, 2025 10:00am
